Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, insights, and strategies to pursue value-driven solutions.

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

Their results argue for a change to parity between small-molecule agents and biologics when it comes to Inflation Reduction ...

Kebilidi is a one-time gene therapy administered directly to the brain in patients with AADC deficiency, rare genetic ...

In a phase 2 trial, a gene therapy reduced angioedema attacks, which could significantly change the quality of life for ...

Patients with metastatic non-small cell lung cancer, even those with brain metastases, experienced improved longer-term ...

In a new study of patients with metastatic non-small cell lung cancer, researchers found that patients who were more physically fit had better outcomes. With lung cancer claiming around 1.8 million ...

After feedback from the FDA, the companies have voluntarily withdrawn the previous biologics licensing application for ...

Seemal Desai, M.D., FAAD, discusses how immune system dysregulation and genetic variants intersect to trigger vitiligo development while highlighting diagnostic challenges including identifying ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, insights, and strategies to pursue value-driven solutions.

Current financial screening procedures in the United States may need to change, according to recent research done by Laila ...

People with multiple sclerosis (MS) often stop taking disease-modifying therapy as they transition from relapsing-remitting MS to secondary progressive MS. This study shows that people who stop stop ...